Cardiff Oncology Inc

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2004-07-27. The firm's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The firm's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.